Literature DB >> 31228294

Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.

Gang Chen1,2, Jonathan D Cook3, Wei Ye1,2, Jeffrey E Lee3, Sachdev S Sidhu1,2.   

Abstract

The HIV fusion inhibitor T20 has been approved to treat those living with HIV/AIDS, but treatment gives rise to resistant viruses. Using combinatorial phage-displayed libraries, we applied a saturation scan approach to dissect the entire T20 sequence for binding to a prefusogenic five-helix bundle (5HB) mimetic of HIV-1 gp41. Our data set compares all possible amino acid substitutions at all positions, and affords a complete view of the complex molecular interactions governing the binding of T20 to 5HB. The scan of T20 revealed that 12 of its 36 positions were conserved for 5HB binding, which cluster into three epitopes: hydrophobic epitopes at the ends and a central dyad of hydrophilic residues. The scan also revealed that the T20 sequence was highly adaptable to mutations at most positions, demonstrating a striking structural plasticity that allows multiple amino acid substitutions at contact points to adapt to conformational changes, and also at noncontact points to fine-tune the interface. Based on the scan result and structural knowledge of the gp41 fusion intermediate, a library was designed with tailored diversity at particular positions of T20 and was used to derive a variant (T20v1) that was found to be a highly effective inhibitor of infection by multiple HIV-1 variants, including a common T20-escape mutant. These findings show that the plasticity of the T20 functional sequence space can be exploited to develop variants that overcome resistance of HIV-1 variants to T20 itself, and demonstrate the utility of saturation scanning for rapid epitope mapping and protein engineering.
© 2019 The Protein Society.

Entities:  

Keywords:  HIV-1; antiviral therapy; fusion inhibitor; peptide engineering; phage display

Mesh:

Substances:

Year:  2019        PMID: 31228294      PMCID: PMC6635768          DOI: 10.1002/pro.3669

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  46 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.

Authors:  Shuwen Liu; Weiguo Jing; Byron Cheung; Hong Lu; Jane Sun; Xuxia Yan; Jinkui Niu; James Farmar; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2007-02-02       Impact factor: 5.157

3.  Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.

Authors:  L Pérez-Alvarez; R Carmona; A Ocampo; A Asorey; C Miralles; S Pérez de Castro; M Pinilla; G Contreras; J A Taboada; R Nájera
Journal:  J Med Virol       Date:  2006-02       Impact factor: 2.327

4.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

Authors:  M K Lawless; S Barney; K I Guthrie; T B Bucy; S R Petteway; G Merutka
Journal:  Biochemistry       Date:  1996-10-22       Impact factor: 3.162

5.  Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.

Authors:  Yuanmei Zhu; Xiujuan Zhang; Xiaohui Ding; Huihui Chong; Sheng Cui; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Biol Chem       Date:  2018-02-07       Impact factor: 5.157

6.  T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

Authors:  Jacob P Lalezari; Nicholaos C Bellos; Kunthavi Sathasivam; Gary J Richmond; Calvin J Cohen; Robert A Myers; David H Henry; Claire Raskino; Tom Melby; Hugh Murchison; Ying Zhang; Rebecca Spence; Michael L Greenberg; Ralph A Demasi; G Diego Miralles
Journal:  J Infect Dis       Date:  2005-02-22       Impact factor: 5.226

7.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

8.  CDR-H3 diversity is not required for antigen recognition by synthetic antibodies.

Authors:  Helena Persson; Wei Ye; Amy Wernimont; Jarrett J Adams; Akiko Koide; Shohei Koide; Robert Lam; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2012-12-03       Impact factor: 5.469

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

View more
  2 in total

1.  HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants.

Authors:  Ana Valadés-Alcaraz; Roberto Reinosa; África Holguín
Journal:  Front Microbiol       Date:  2022-05-27       Impact factor: 6.064

Review 2.  Will Peptides Help to Stop COVID-19?

Authors:  Viktoriya G Krut'; Sergei A Chuvpilo; Irina V Astrakhantseva; Liubov I Kozlovskaya; Grigory A Efimov; Andrei A Kruglov; Marina S Drutskaya; Sergei A Nedospasov
Journal:  Biochemistry (Mosc)       Date:  2022-07       Impact factor: 2.824

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.